Cancer lead SW GMSA Patients at the heart of change Patients expect clinical teams to know the best treatment for them in order to get the best outcomes Clinicians need all the clinical information ID: 1041347
Download Presentation The PPT/PDF document "Head and Neck CAG Frank McDermott" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Head and Neck CAGFrank McDermottCancer lead SW GMSA
2. Patients at the heart of changePatients expect clinical teams to know the best treatment for them in order to get the best outcomesClinicians need all the clinical information together in order to make the best treatment decisions for individual patientsResearch requires the right patients to enter trials to move best treatments forward for patients Slide by Louise Medley
3.
4.
5. Hallmarks of Cancer: The Next GenerationHanahan et al CellVolume 144, Issue 5, p646–674, 4 March 2011
6.
7. GLH/ GMSA
8. Current TestingWGS – Sarcoma, haemonc, paediatric cancersSolid tumours – TSO 500 gene panelOther tests e.g. DPYD
9. TruSight Oncology 500 (TSO500)Pan-cancer NGS assay using DNA and RNA simultaneouslyTargets 523 genes for SNV’s, indels & CNVs and 55 genes for fusionsCaptures known and novel fusionsIncludes key and emerging biomarkers Anatomical sites include (but not limited to):9 Mainstreaming genomic medicine
10. https://www.england.nhs.uk/publication/national-genomic-test-directories/ National Genomic Test Directory
11. Head and Neck SCC
12.
13. Thyroid Papillary
14. DPYDDihydropyrimidine dehydrogenase (DPD), an enzyme encoded by the DPYD gene, is the rate limiting stepDeactivates more than 80% of standard doses of 5FU and the oral 5FU prodrug capecitabine
15.
16. Neurotrophic Receptor Tyrosine Kinase 1,2,3 (NTRK)Chromosomal translocation – oncogenic properties. All cancer 0.3%Salivary gland 2.6%Thyroid 1.6%Potential target for TRK inhibitionTRK inhibition e.g. Larotrectinib / entrectinib
17. GLH: https://www.nbt.nhs.uk/south-west-genomic-laboratory-hub
18. Future & ChallengesExpansion of testingCarcinoma unknown primaryctDNA/ MRDGTABsCancer eventMy email: f.mcdermott@nhs.net
19. Resourceshttps://www.genomicseducation.hee.nhs.uk/